TrialsgrambetaRCTs are beautiful

Study 31 / A5349

2021

Four-Month Rifapentine-Based Regimen for Drug-Susceptible TB

In 2,516 patients with drug-susceptible pulmonary tuberculosis, a 4-month regimen of high-dose rifapentine plus moxifloxacin was non-inferior to the standard 6-month regimen for TB-free survival.

Result

Relapse-free cure at 12 months
Absolute difference
1 points

The absolute difference is derived from the event rates.

Also reported: Non-inferior.

Original publication
Subtopic
Drug-susceptible TB
Design
Open-label non-inferiority RCT
Relevance
Important: one of several pillars.
Source
Dorman SE, et al. N Engl J Med. 2021;384(18):1705-1718.doi 10.1056/NEJMoa2033400

Discussion & critique

First WHO- and CDC-endorsed 4-month regimen for drug-susceptible pulmonary TB in patients ≥12 years, a major step from 6 to 4 months.

Discussed in podcasts